Presentation of preclinical data for AB-101, a clinical-stage, ADCC-enhancer, allogeneic, off-the-shelf NK cell therapy candidate developed with Artiva’s AlloNKTM Platform Data highlights the optimized cell profile of AB-101 and combination data with monoclonal antibodies rituximab, obinutuzumab, cetuximab, and trastuzumab SAN DIEGO, November 10, 2022 – Artiva Biotherapeutics, Inc., a clinical stage company whose mission is…
Companies to combine their clinical programs (AFM13, AB-101) to address high unmet need of CD30-positive lymphoma patients Affimed’s AFM13 in combination with cord blood-derived NK cells demonstrated exceptionally high response rates in relapsed and refractory CD30-positive lymphoma patients AB-101 is a clinical-stage, cryopreserved, off-the shelf, non-genetically modified, allogeneic cord blood-derived NK cell manufactured at large…
Data describe the preclinical activity of AB-101, an allogeneic NK cell product candidate, in combination with CD38 therapeutic antibodies in multiple myeloma model systems without the need for CD38 editing SAN DIEGO, November 3, 2022 – Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK)…